Immuron Limited Emerging Growth Conference Presentation

Immuron Limited, an Australian biopharmaceutical company, announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference on October 22, 2025. The presentation will focus on Immuron's development and commercialization of orally delivered targeted polyclonal antibodies for treating infectious diseases. Key products include Travelan®, which reduces the risk of travelers' diarrhea, and ProIBS®, aimed at treating irritable bowel syndrome. The company also highlighted its ongoing clinical trials and anticipated milestones, including FDA approval for IMM-529, a treatment for Clostridioides difficile infection. Immuron reported a 49% increase in global sales revenue for FY2025, driven by strong performance in Australia and North America.